Entera Bio Ltd (ENTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Entera Bio Ltd (ENTX) has a cash flow conversion efficiency ratio of -0.180x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.74 Million) by net assets ($15.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ENTX net asset quality score to measure how much of total assets are equity-financed.
Entera Bio Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Entera Bio Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Entera Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entera Bio Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deniz Gayrimenkul Yatirim Ortakligi AS
IS:DZGYO
|
0.068x |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
0.065x |
|
Solutions 30 SE
F:30L3
|
-0.234x |
|
Dynamic Medical Technologies
TWO:4138
|
0.130x |
|
Clene Inc.
NASDAQ:CLNN
|
0.241x |
|
HLB Life Science Co. Ltd
KQ:067630
|
-0.016x |
|
Castellum Inc.
NYSE MKT:CTM
|
0.036x |
|
EuroDry Ltd
NASDAQ:EDRY
|
0.074x |
Annual Cash Flow Conversion Efficiency for Entera Bio Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Entera Bio Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Entera Bio Ltd (ENTX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.08 Million | $-6.82 Million | -0.844x | -19.89% |
| 2023-12-31 | $10.39 Million | $-7.31 Million | -0.704x | +33.81% |
| 2022-12-31 | $11.75 Million | $-12.50 Million | -1.063x | -164.76% |
| 2021-12-31 | $22.57 Million | $-9.06 Million | -0.402x | +71.43% |
| 2020-12-31 | $7.51 Million | $-10.56 Million | -1.406x | -87.86% |
| 2019-12-31 | $11.92 Million | $-8.92 Million | -0.748x | +22.73% |
| 2018-12-31 | $10.12 Million | $-9.80 Million | -0.968x | -775.20% |
| 2017-12-31 | $-31.56 Million | $-4.53 Million | 0.143x | +15.24% |
| 2016-12-31 | $-25.25 Million | $-3.14 Million | 0.124x | -8.53% |
| 2015-12-31 | $-25.69 Million | $-3.50 Million | 0.136x | -- |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more